Recommended Tranexamic Acid Treatment for Heavy Menstrual Cycles
For heavy menstrual bleeding, prescribe tranexamic acid 3.9-4 grams per day orally (typically 1.3 grams three times daily or 650 mg four times daily) for 4-5 consecutive days starting on the first day of menstruation. 1, 2
Dosing Regimen
- Start therapy on day 1 of menstrual bleeding and continue for 4-5 consecutive days only (maximum 15 doses per cycle) 1, 3
- The total daily dose of 3.9-4 grams can be divided as 1.3 grams three times daily 2, 4, 3
- Treatment is taken only during active bleeding days, not continuously throughout the month 2
Expected Efficacy
- Tranexamic acid reduces menstrual blood loss by 34-60% compared to baseline 2, 5, 6
- In the highest quality randomized controlled trial, women experienced a 40.4% reduction in menstrual blood loss (mean reduction of 69.6 mL) compared to 8.2% with placebo 4
- Improvements in quality of life measures occur within the first treatment cycle and are maintained long-term 4, 3
Absolute Contraindications - Screen Before Prescribing
- Active thromboembolic disease or disseminated intravascular coagulation 2
- History of thrombosis or thromboembolism 1, 5
- Intrinsic risk factors for thrombosis or thromboembolism 1, 5
- Cardiovascular disease, including spontaneous coronary artery dissection - tranexamic acid should generally be avoided given association with MI and thrombosis 7, 2
Important Clinical Distinctions
Do not confuse menorrhagia dosing with postpartum hemorrhage dosing - the WHO postpartum hemorrhage protocol uses 1 gram IV over 10 minutes (completely different route, dose, and indication) 1
Monitoring and Reassessment
- Assess renal function before initiating therapy - impaired renal function increases risk of neurotoxicity and ocular toxicity requiring dose reduction 2
- Reassess efficacy after 2-3 treatment cycles 1
- Consider alternative therapy if bleeding remains unacceptable after an adequate trial period 1
Alternative Therapies if Tranexamic Acid Fails or is Contraindicated
- Levonorgestrel-releasing intrauterine device (LNG-IUD 20 μg/day) is more effective than tranexamic acid, reducing menstrual blood loss by 71-95%, and may be particularly useful in women with cardiovascular contraindications to tranexamic acid 7, 2, 5
- NSAIDs (mefenamic acid or naproxen) are less effective than tranexamic acid but can be considered, though they should be avoided in patients with cardiovascular disease 2, 8
Safety Profile
- Adverse effects are predominantly mild to moderate gastrointestinal symptoms (nausea, vomiting, diarrhea, dyspepsia) occurring in approximately 12% of patients 8
- No evidence of increased thromboembolic events in clinical trials of women treated for menorrhagia 5, 6
- Long-term treatment over 27 cycles demonstrated good tolerability with most adverse events unrelated to study treatment 3